February 2020 Vol 6 No 1
Issue Introductions
Hello everyone and welcome to our February 2020 issue of CONQUER: the patient voice! Once again, we have packed many articles into this new issue to empower you with information, provide hope through inspirational stories from others, and perhaps help you look at the world with a different perspective.
Infusion of HopePatient Stories
Cancer survivor Tricia Tennesen recounts her spirit-lifting experience with a group of survivors on a nature retreat that involved fly-fishing, which offered her a “path to spirituality without doctrine or dogma.”
Patient StoriesOvarian Cancer
By Gail Silver
Julie Silver ran into many “bumps in the road” after she was diagnosed with stage IV ovarian cancer. Despite many difficulties along the way, today her life is filled with gratitude and appreciation.
Family Members
By Paul Kidwell
Paul Kidwell shares his devastating experience at a family gathering for his 31-year-old nephew, who was diagnosed with stage IV colorectal cancer at age 25 and had only weeks to live.
Immunotherapy
Immunotherapy is offering exciting new treatments for many types of cancer. It works by revving up the immune system and can have various side effects in different patients.
Multiple Myeloma
Many medications for multiple myeloma have been approved in recent years. That is great for patients, but it becomes even more important that doctors choose the best treatment for each patient.
MesotheliomaSurvivorship
Emily Ward was diagnosed with mesothelioma, a type of cancer usually associated with men who are exposed to asbestos. After working as a nurse for more than 40 years, her surprising diagnosis led to a search for the best care possible.
Breast Cancer
New evidence shows that the use of some permanent hair colors may be associated with increased risk of breast cancer.
Leukemia
By Dana Taylor
Calquence, a new-generation targeted therapy recently approved for the treatment of CLL, has shown good results in a 3-drug combination therapy.
Leukemia
By Dana Taylor
Brukinsa, which was approved for use in patients with mantle-cell leukemia in late 2019, has also showed promising results in 2 recent clinical trials of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), including patients with high-risk genetic abnormalities.
- 1
- 2
Page 1 of 2
Results 1 - 10 of 17
Results 1 - 10 of 17